| pubmed-article:348308 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:348308 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:348308 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:348308 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:348308 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:348308 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:348308 | pubmed:dateCreated | 1978-7-15 | lld:pubmed |
| pubmed-article:348308 | pubmed:abstractText | Twenty-six patients with metastatic breast cancer received cis-dichlorodiammineplatinum(II) either as a single dose of 100 mg/m2 iv every 3--4 weeks or as a continuous 5-day infusion of 20 mg/m2/day at 4-week intervals. Fourteen patients were treated with the single-dose schedule and 12 patients were treated with the continuous 5-day infusion. No significant response was observed with either dose schedule. Aside from a reduction in the frequency and severity of gastrointestinal toxicity with the continuous 5-day infusion, no real difference was seen with regard to renal and hematologic toxicity with either dose schedule. | lld:pubmed |
| pubmed-article:348308 | pubmed:language | eng | lld:pubmed |
| pubmed-article:348308 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:348308 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:348308 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:348308 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:348308 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:348308 | pubmed:issn | 0361-5960 | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:BlumenscheinG... | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:TashimaC KCK | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:HortobagyiG... | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:BuzdarA UAU | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:YapH YHY | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:SalehWW | lld:pubmed |
| pubmed-article:348308 | pubmed:author | pubmed-author:BodeyG PGPSr | lld:pubmed |
| pubmed-article:348308 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:348308 | pubmed:volume | 62 | lld:pubmed |
| pubmed-article:348308 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:348308 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:348308 | pubmed:pagination | 405-8 | lld:pubmed |
| pubmed-article:348308 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:348308 | pubmed:meshHeading | pubmed-meshheading:348308-H... | lld:pubmed |
| pubmed-article:348308 | pubmed:meshHeading | pubmed-meshheading:348308-B... | lld:pubmed |
| pubmed-article:348308 | pubmed:meshHeading | pubmed-meshheading:348308-C... | lld:pubmed |
| pubmed-article:348308 | pubmed:meshHeading | pubmed-meshheading:348308-D... | lld:pubmed |
| pubmed-article:348308 | pubmed:meshHeading | pubmed-meshheading:348308-C... | lld:pubmed |
| pubmed-article:348308 | pubmed:year | 1978 | lld:pubmed |
| pubmed-article:348308 | pubmed:articleTitle | Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. | lld:pubmed |
| pubmed-article:348308 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:348308 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:348308 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:348308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:348308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:348308 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:348308 | lld:pubmed |
